Pfizer and the French and Swiss company Valneva claim that trials showed 70 percent effectiveness in people aged five and older.
Read more 135 million euros offered for the bankrupt Estonian «E-Piim Tootmine» factories
Currently, there are no approved vaccines for Lyme disease.
Despite disappointing trial results earlier this year, the European Medicines Agency (EMA) has accepted an application to approve the preparation officially called PF-07307405, these two companies announce.
Although Lyme disease is rarely fatal, a bite from an infected tick can cause rashes and flu-like symptoms, and in some cases – neurological problems.
“We believe that vaccination can provide an important new level of protection against this debilitating disease,” Pfizer’s chief vaccine officer Annaliesa Anderson said in a joint statement.
Read more Friday accident on the Vilnius–Panevėžys route: one car flew off the highway
According to 2022 research data, more than 14 percent of the world’s population has had this disease, and it is warned that transmission rates may increase as summers become longer and drier due to climate change.
Following this news, Valneva shares rose nearly 16 percent at the start of trading on the Paris Stock Exchange on Friday.
The EMA’s decision to accept the application “is a huge achievement, especially considering that more than 200 million people in Europe live in Lyme disease risk areas,” Valneva CEO Thomas Lingelbach said in a statement.
